Objective: To evaluate hypoechoic lesion in transrectal ultrasonography of prostate (TRUS-P) predictive value on prostate cancer based on PSA Interval and Gleason Group. Material & Methods: An observational analytic study with a cross-sectional design take place from January 2015 to December 2018 analyzing patients who had undergone TRUS-P Biopsy at Hasan Sadikin Hospital. Patients are divided into several subgroups according to different PSA levels. A p-value < 0.05 was considered statistically significant. PPV, NPV, and Youden’s index were all indexes reflecting the performance of a diagnostic test. Results: There were 35 cases (49.3%) with a visible hypoechoic lesion in TRUS and 36 cases (41.7%) without a visible hypoechoic lesion. In our study, 23.9% of the patients with hypoechoic lesions were diagnosed with prostate cancer on TRUSP-Biopsy. The results of the analysis with Youden’s index show that PSA at intervals of 10-20 is the best predictor of diagnostic values. Then we analyzed the overall detection rate based on PSA interval. Patients with PSA > 20 ng/ml, hypoechoic lesions were significantly associated with Gleason Group. Conclusion: We concluded in our study that the hypoechoic lesion in transurethral ultrasonography of prostate could improve the predictive efficacy for diagnosing prostate cancer.
Prostate Cancer, Ultrasonography, Hypoechoic Lesion
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7.
Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries; 2018. p. 1–31.
Birs A, Joyce PH, Pavlovic ZJ, Lim A. Diagnosis and monitoring of prostatic lesions: a comparison of three modalities: multiparametric MRI, fusion MRI/transrectal ultrasound (TRUS), and traditional TRUS. Cureus. 2016; 8: e702.
Lee DH, Nam JK, Park SW. Visually estimated MRI targeted prostate biopsy could improve the detection of significant prostate cancer in patients with a PSA level < 10 ng/mL. Yonsei Med J. 2016; 57: 565–71.
Pallwein L, Mitterberger M, Pelzer A, Bartsch G, Strasser H, Pinggera GM, et al. Ultrasound of prostate cancer: recent advances. Eur Radiol. 2008; 18: 707–15.
Sathianathen, N. J., Konety, B. R., Crook, J., Saad, F., & Lawrentschuk, N. Landmarks in prostate cancer. Nature Reviews Urology; 2018.